[Multiple myeloma].
Multiple myeloma causes debilitating clinical symptoms including intractable bone pain, disabling multiple fractures and hypercalcemia. Bisphosphonates, potent inhibitors of osteoclast-mediated bone destruction, prevent skeletal-related events in myeloma. However, the impact of long-term bisphosphonate use remains unclear because of insufficient follow-up, while osteonecrosis of the jaw (ONJ) emerges as a major concern. The proteosome inhibitor bortezomib is a novel anti-myeloma agent, which has been recently drawn a considerable attention in its anabolic effects to resume bone formation in patients with myeloma. It is important to clarify the roles of these bone-targeting agents in the treatment for a myeloma bone disease and make the best use of them by eliminating underlying risk of their adverse effects.
Abe
Masahiro
M
Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine.
D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D007571:Jaw Diseases / Q000139:chemically induced; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib